43 filings
Page 2 of 3
6-K
pwkc8on0o0spdn9
30 Apr 21
Current report (foreign)
8:00am
6-K
er60tm
6 Apr 21
Stealth Biotherapeutics Reports Fiscal Year 2020 Financial Results and Recent Business Highlights
8:06am
6-K
rcrcn59 lsc0j
11 Feb 21
Securities Purchase Agreement
8:04am
6-K
tuyf9cgcgp9axainp
7 Dec 20
Stealth BioTherapeutics Announces Appointment of Eve E. Slater, M.D., F.A.C.C. to its Board of Directors
4:20pm
6-K
53ajl2w
23 Nov 20
Securities Purchase Agreement
4:05pm
6-K
vstcl2wn
19 Nov 20
Current report (foreign)
5:16pm
6-K
mo7sosjn4r5vtmv0
5 Nov 20
Stealth Biotherapeutics Reports Third Quarter 2020 Financial Results and Recent Business Highlights
8:06am
6-K
dgcoku x2bur8
4 Nov 20
6-K for Transaction
5:18pm
6-K
faqoh3 zkk3
7 Aug 20
Current report (foreign)
12:00am
6-K
djp6iescch5gfp2i0r1
6 Aug 20
Stealth Biotherapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights
8:00am
6-K
dscflxh0
3 Jun 20
Current report (foreign)
4:06pm
6-K
6p5kux hg
7 May 20
Stealth Biotherapeutics Reports First Quarter 2020
8:20am
6-K
k83a3ajn
13 Apr 20
Stealth Biotherapeutics Announces $20 Million Financing to
8:38am
6-K
gmrpsc4sdwgo3oar8
3 Apr 20
Current report (foreign)
4:02pm
6-K
ehdx c27a79027
16 Mar 20
Current report (foreign)
7:47am
6-K
x1us05j okacckuevvme
7 Jan 20
Current report (foreign)
5:18pm
6-K
5nnk xn7suimi
20 Dec 19
Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy
5:09pm
6-K
f22qo ea055mnyq
14 Nov 19
Stealth Biotherapeutics Reports Third Quarter 2019
8:00am
6-K
d7b83r8tm 3pihb
10 Oct 19
Alexion and Stealth Announce Agreement for Option toCo-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
8:15am
6-K
bpxqtd u1
3 Sep 19
Stealth Biotherapeutics Announces Appointment of Robert
5:20pm